JP2024533109A5 - - Google Patents

Info

Publication number
JP2024533109A5
JP2024533109A5 JP2024513689A JP2024513689A JP2024533109A5 JP 2024533109 A5 JP2024533109 A5 JP 2024533109A5 JP 2024513689 A JP2024513689 A JP 2024513689A JP 2024513689 A JP2024513689 A JP 2024513689A JP 2024533109 A5 JP2024533109 A5 JP 2024533109A5
Authority
JP
Japan
Prior art keywords
ada
recombinant protein
cell according
human
operably linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533109A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042193 external-priority patent/WO2023034408A1/en
Publication of JP2024533109A publication Critical patent/JP2024533109A/ja
Publication of JP2024533109A5 publication Critical patent/JP2024533109A5/ja
Pending legal-status Critical Current

Links

JP2024513689A 2021-08-31 2022-08-31 キメラ抗原受容体(car)t細胞療法プラットフォーム Pending JP2024533109A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163238927P 2021-08-31 2021-08-31
US63/238,927 2021-08-31
US202263355396P 2022-06-24 2022-06-24
US63/355,396 2022-06-24
PCT/US2022/042193 WO2023034408A1 (en) 2021-08-31 2022-08-31 Chimeric antigen receptor (car) t cell therapy platform

Publications (2)

Publication Number Publication Date
JP2024533109A JP2024533109A (ja) 2024-09-12
JP2024533109A5 true JP2024533109A5 (cg-RX-API-DMAC7.html) 2025-09-04

Family

ID=85411600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513689A Pending JP2024533109A (ja) 2021-08-31 2022-08-31 キメラ抗原受容体(car)t細胞療法プラットフォーム

Country Status (5)

Country Link
US (1) US20240350546A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396341A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533109A (cg-RX-API-DMAC7.html)
KR (1) KR20240050428A (cg-RX-API-DMAC7.html)
WO (1) WO2023034408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134998A1 (en) * 2021-08-30 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University T cells with cell-surface expression of adenosine deaminase and uses thereof
WO2026035304A1 (en) * 2024-04-08 2026-02-12 Gemini Corp. Medical modeling architecture, intelligence and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
CN112672753B (zh) * 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
US12600971B2 (en) * 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US20250134998A1 (en) * 2021-08-30 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University T cells with cell-surface expression of adenosine deaminase and uses thereof

Similar Documents

Publication Publication Date Title
ES2276735T3 (es) Anticuerpos fv multimericos de cadena sencilla en tandem.
Morrison In vitro antibodies: strategies for production and application
Pavlinkova et al. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts
US5767260A (en) Antigen-binding fusion proteins
EP3057991B1 (en) Chimeric antigen receptor t cell switches and uses thereof
JP5938473B2 (ja) 多価抗原結合Fv分子
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
CA3148621A1 (en) Compositions and methods comprising protease-activated therapeutic agents
JP2019137675A5 (cg-RX-API-DMAC7.html)
JP2009523459A5 (cg-RX-API-DMAC7.html)
JP2010522701A5 (cg-RX-API-DMAC7.html)
JP2001095566A (ja) サイトカインの免疫複合体
JP2003292458A (ja) 細胞毒性剤治療
CN117255691A (zh) 干扰素前药、制备方法及应用
JP7247113B2 (ja) ミクログリアの活性化を抑制する方法
WO2021082573A1 (zh) 抗il-4r单域抗体及其应用
US12410225B2 (en) Modulation of dendritic cell lineages
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
JP2013193995A (ja) 特発性炎症性筋疾患の予防又は治療剤
CN103179987A (zh) 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物
JPWO2006046661A1 (ja) インターロイキン−6阻害剤
JP2022513321A5 (cg-RX-API-DMAC7.html)
CN120399078B (zh) 靶向cd117的纳米抗体及其应用
Xiang Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins
JP2024527571A (ja) インターロイキン-1アルファキメラタンパク質